Establishment of a leukemia model mouse by introducing mutated FLT3 gene
Establishment of a leukemia model mouse by introducing mutated FLT3 gene
批准号:
13671058
负责人:
NAOE Tomoki
金额:
$2.62万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002
中文摘要
到目前为止,迫切需要开发一种新的治疗策略,以肿瘤发生相关的分子为靶点。在白血病中,全反式维甲酸和伊马替尼分别对急性早幼粒细胞白血病和慢性粒细胞白血病或急性淋巴细胞白血病bcr/abl易位有较好的疗效。由于Flt3基因突变是一种预后不良的因素,约30%的成人AML患者与Flt3基因突变有关,针对突变的Flt3基因突变的新型治疗药物的开发将为预后不良的AML患者带来巨大好处。然而,为了分析突变的Flt3基因的生物学效应,以及评价Flt3靶向药物的体内药理作用,有必要通过引入突变的Flt3基因建立白血病模型小鼠。在本研究中,我们试图通过in…建立突变的flt3基因转基因小鼠和骨髓移植模型。构建了3种含SR-α,β-肌动蛋白和组织蛋白酶-G启动子的突变flt3表达载体,构建了突变的flt3转基因小鼠。虽然突变的Flt3基因在SR-α启动子下获得了成功的转基因,但由于Flt3基因的高表达干扰了生殖细胞的功能,未能获得创建者。另一方面,我们可以在β-肌动蛋白和组织蛋白酶-G启动子的作用下,建立几个表达突变的flt3基因的菌株。虽然这些菌株表达突变的Flt3基因,但突变的Flt3蛋白产物较弱。然而,有几个菌株发生了类似CLL的疾病。据报道,移植了表达突变的Flt3干细胞的小鼠患上了非克隆性骨髓增殖性疾病,但没有急性髓系白血病。因此,严格调控突变的Flt3基因的表达水平对于建立AML模型小鼠具有重要意义。较少
英文摘要
To date, the development of a novel therapeutic strategy, which targets the molecule associated with tumorigenesis, is strongly required. In leukemia, it is well known that all-trans retinoic acid and imatinib bring the superior effects to acute promyelocytic leukemia and chronic myeloid leukemia or acute lymphoblastic leukemia with the BCR/ABL translocation, respectively. Since FLT3 gene mutation is a poor prognostic factor which is involved in about 30% of the adult AML, the development of the novel therapeutic agents, which target to mutated FLT3, will succeed in the great benefits to the AML patients with poor prognostic factors. However, it is necessary to establish the leukemia-model mouse by introducing the mutated FLT3 gene for analyzing the biological effects from the mutated FLT3 and evaluating the pharmacological effects of the FLT3-targeted agents in vivo. In this study, we tried to establish the mutated FLT3 gene transgenic mouse and bone marrow transplantation model by in … More troducing the mutated FLT3 gene into mouse hematopoietic stem cells.We constructed three kinds of mutated FLT3-expression vectors, which contained SR-α, β-actin and cathepsin-G promoter, respectively and subjected to produce the mutated FLT3-transgenic mice. Although the transgene of the mutated FLT3 was successful under the SR-α promoter, we could not obtained the founder because the generative cell function was disturbed due to the high expression of FLT3. On the other hand, we could established several founders expressing mutant FLT3 gene under β-actin and cathepsin-G promoters. Although these strains expressed mutated FLT3 mRNA, protein products of mutated FLT3 were faint. However, several strains developed CLL like disease. It has been reported that mice transplanted with mutant FLT3 expresseing stem cells developed non-clonal myeloproliferative disease, but not AML. Therefore, it is thought to be important for production of an AML model mouse to strictly regulate the expression level of mutated FLT3. Less
期刊论文(52)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T: "Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain"Oncogene. 21. 2555-2563 (2002)
Kiyoi H、Ohno R、Ueda R、Saito H、Naoe T:“近膜结构域中具有内部串联复制的 FLT3 组成型激活机制”癌基因。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hansen-Hagge E.Thomas: "Disruption of the RanBP17/Hox11L2 region by recombination with the TCRd locus in acute lymphoblastic leukemias with t (5;4) (q34;q11)"Leukemia. 16. 2205-2212 (2002)
Hansen-Hagge E.Thomas:“在患有 t (5;4) (q34;q11) 的急性淋巴细胞白血病中,通过与 TCRd 位点重组而破坏 RanBP17/Hox11L2 区域”。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hitoshi Kiyoi: "Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain"Oncogene. 21. 2555-2563 (2002)
Hitoshi Kiyoi:“FLT3 的组成型激活机制与近膜结构域中的内部串联复制”癌基因。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hanamura I: "Ectopic expression of MAFB gene in human myeloma cells carrying (14;20) (q32;q11) chromosomal translocations"Jpn J Cancer Res. 92. 638-644 (2001)
Hanamura I:“携带 (14;20) (q32;q11) 染色体易位的人骨髓瘤细胞中 MAFB 基因的异位表达”Jpn J Cancer Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hitoshi Kiyoi: "Immunoglobulin variable region structure and B-cell malignancies"Int J Hematol. 73. 47-53 (2001)
Hitoshi Kiyoi:“免疫球蛋白可变区结构和 B 细胞恶性肿瘤”Int J Hematol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 49 条
Translational research toward drug discovery of leukemia
-
批准号:25293218
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.9万
-
财政年份:2013
-
负责人:NAOE Tomoki
-
依托单位:
Development of innovative anti-tumor agents that target signal transducers and activator of transcription
-
批准号:23659487
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:NAOE Tomoki
-
依托单位:
Basic research aimed at understanding and overcoming of the primary and secondary resistance in molecular target therapy
-
批准号:22390192
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.98万
-
财政年份:2010
-
负责人:NAOE Tomoki
-
依托单位:
Molecular mechanisms and therapeutic approach of residual leukemia
-
批准号:19390261
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.98万
-
财政年份:2007
-
负责人:NAOE Tomoki
-
依托单位:
Research & Development of molecular target therapy for leukemia and Its assessment System
-
批准号:17016029
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$29.38万
-
财政年份:2005
-
负责人:NAOE Tomoki
-
依托单位:
Analysis of aberrant signal tansduction in hematological malignancy and development of treatment methods.
-
批准号:16390276
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.81万
-
财政年份:2004
-
负责人:NAOE Tomoki
-
依托单位:
Involvement of Fas ligand-independent caspase8 activation in AsィイD22ィエD2OィイD23ィエD2-induced apoptosis
-
批准号:10670940
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.6万
-
财政年份:1998
-
负责人:NAOE Tomoki
-
依托单位:
海外基金